Geneva, Switzerland, 28 July 2016 – ObsEva, a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to…
Month: July 2016
ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis
Geneva, Switzerland, 06 July, 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that its…